Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age.
Jakimovski D, Kavak KS, Vaughn CB, Goodman AD, Coyle PK, Krupp L, Gottesman M, Edwards KR, Lenihan M, Perel A, Zivadinov R, Weinstock-Guttman B; New York State Multiple Sclerosis Consortium (NYSMSC).
Jakimovski D, et al. Among authors: vaughn cb.
Mult Scler Relat Disord. 2022 Jan;57:103406. doi: 10.1016/j.msard.2021.103406. Epub 2021 Nov 16.
Mult Scler Relat Disord. 2022.
PMID: 34915316